Can I get it?
Not for this use. Tesamorelin has no EU authorisation for it, so it cannot be prescribed or dispensed here for that purpose.
Why buying it online is risky
Tesamorelin · Portugal
Tesamorelin in Portugal.
Not something we can prescribe. Our doctors can review your case for an EU-approved treatment instead.
Full refund if a review is not approved
NOT AVAILABLE TODAY
Hi-Doctor does not prescribe Tesamorelin.
Our licensed doctors currently focus on three areas with solid clinical evidence and a clear EU regulatory framework. We extend the catalogue as specialists join and regulation allows. Tesamorelin is outside the current scope.
Buying Tesamorelin online without a valid prescription carries counterfeiting and toxicity risks. Always consult a licensed healthcare professional.
IN PLAIN TERMS
What Tesamorelin is, and how to get treatment
Tesamorelin is a laboratory-made copy of growth-hormone-releasing hormone. It is approved in the United States, under the brand name Egrifta, for one narrow purpose: reducing excess abdominal fat in people with HIV who have lipodystrophy. It is not authorised in the European Union — the application was withdrawn in 2012 after the EMA's expert committee said it could not have been approved, citing a rise in IGF-1 as a major safety concern and doubt that the fat reduction brought a real health benefit — so no doctor here can prescribe it. It is not a general weight-loss medicine, and the vials sold by online peptide sellers are unlicensed material whose contents cannot be verified.
Tesamorelin has no EU marketing authorisation for this use. It may be an approved medicine for something else, or approved in another country — but not something a doctor here can prescribe for this.
What can I take instead?
Semaglutide is approved in the EU, has published peer-reviewed trial results, and can be prescribed today if a doctor decides it suits you.
Read about SemaglutideWhat do the studies show?
Every trial behind Tesamorelin is listed below with its registry number, how many people took part, and whether the results are peer-reviewed or a company announcement.
Jump to the studiesWHAT WE DO COVER
If your question fits one of these three areas, a licensed doctor reviews it in less than 2 hours on average for €35.
TREATMENTS
Three categories, one process.
Choose what fits. The journey is identical.
ONGOING PLANWeight loss
A medical consultation on your weight goal. Treatment if appropriate.
€25/month28-day treatment cycle
Explore weight lossONE-OFFSexual health
An absolutely discreet consultation for intimate concerns.
€35 one-offFull refund if not approved
Explore sexual healthONGOING PLANHair growth
Medical assessment and tailored treatment for hair loss.
€15/monthBilled €45 every 90 days
Explore hair growthLicensed EU doctors
Doctor review in less than 2 hours on average
50,000+ patients served
Secure patient account
VERIFIED EVIDENCE
Tesamorelin: evidence and regulatory guide.
WHAT IT IS
How it works
A laboratory-made analogue of growth-hormone-releasing hormone; it acts on the pituitary gland's GHRH receptor to increase release of the body's own growth hormone, which in turn increases the breakdown of fat tissue.
- GHRH receptor (GHRHR)
DEVELOPMENT STAGE
Not marketed in the EU
Trial register2 registered trials
Every NCT identifier links to its ClinicalTrials.gov record. A readout is not the same as peer-reviewed publication.
| TRIAL / NCT | POPULATION | PARTICIPANTS | STATUS | READOUT / COMPLETION |
|---|---|---|---|---|
| Phase 3 trial of tesamorelin in HIV-associated abdominal fat accumulationNCT00123253 | Adults with HIV on antiretroviral therapy who had excess abdominal fat | 412 | Read out | 2007-12-06 |
| Phase 3 extension study of tesamorelin (TH9507)NCT00608023 | Adults with HIV on antiretroviral therapy who had excess abdominal fat | 263 | Read out | 2010-09-01 |
What the studies reported
Results are grouped by source and evidence grade so journal data and manufacturer announcements cannot be confused.
Peer-reviewed
Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. doi:10.1056/NEJMoa072375| DOSE OR GROUP | MEAN WEIGHT CHANGE | WEEKS |
|---|---|---|
| 2 mg daily, subcutaneous | Visceral adipose tissue changed by −15.2% versus +5.0% on placebo | 26 |
| 2 mg daily, subcutaneous | IGF-I changed by +81.0% versus −5.0% on placebo | 26 |
This was studied only in adults with HIV on antiretroviral therapy who had excess abdominal fat; when the EU application was assessed, the CHMP said the fat reduction had not been shown to be clinically meaningful in terms of actual health benefits, and that the trial participants were not representative of European HIV patients.
Sources
Last reviewed 2026-07-27
- EMA — Questions and answers: Withdrawal of the marketing authorisation application for Egrifta (tesamorelin), EMA/CHMP/475021/2012, 12 July 2012
- EMA — Ferrer Internacional, S.A. withdraws its marketing authorisation application for Egrifta (tesamorelin), 26 June 2012
- FDA Drugs@FDA — EGRIFTA (tesamorelin acetate), BLA 022505, Theratechnologies, original approval 10 November 2010
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370
- Falutz J, et al. Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-4304
- ClinicalTrials.gov — NCT00123253, phase 3 study of TH9507 in HIV-associated lipodystrophy, 412 participants
- ClinicalTrials.gov · NCT00123253
- ClinicalTrials.gov · NCT00608023
NAMED SAFETY SIGNALS
What has been reported with Tesamorelin.
Rise in IGF-1 was the EMA's main safety concern
The CHMP noted "an increase in the level of a protein called insulin-like growth factor 1 (IGF-1) in a considerable number of patients", that "high levels of IGF-1 may be associated with an increased risk of cancer and a potential worsening of diabetic eye disease", and considered this "a major safety concern".
No long-term safety data
The CHMP recorded that "no long-term safety data were provided, although treatment with Egrifta was expected to be long term", and concluded that the benefits did not outweigh the risks.
Withdrawals for adverse events in the pivotal trial
In the 26-week phase 3 trial, overall adverse events did not differ significantly between groups, but more participants on tesamorelin than on placebo withdrew because of an adverse event.
Not a general weight-loss medicine
The approved US indication is reduction of excess visceral abdominal fat in people with HIV who have lipodystrophy. It has not been shown to work for general weight loss, and the CHMP specifically raised the difficulty of distinguishing lipodystrophy from ordinary obesity.
Unregulated supply
Tesamorelin sold by online peptide sellers is unlicensed material made outside medicines manufacturing rules, so its strength, purity and contents are unverifiable.
UNAPPROVED PRODUCTS ONLINE
Why buying Tesamorelin online is not a shortcut.
No doctor in the EU can prescribe it for this use — including ours. It may be authorised in another country, or for a different condition.
Check the EU common logo
A legitimate online pharmacy in the EU must display the common logo linked to its national register. The logo is a verification check; it cannot make an unapproved medicine legal.
How the EU common logo worksHOW IT WORKS · 5 STEPS
Five steps. No waiting room.
From the online consultation to ongoing follow-up — without leaving home.
- 5 minutes
Start your online visit
Answer a 5-minute health questionnaire from home.
- Less than 2 hours
A doctor reviews your case
A licensed doctor reviews your answers and replies personally.
- Refund guarantee
Review and payment
If not approved, we refund your €35 one-off in full.
- EU pharmacies
Collect treatment from the pharmacy
Collect it at any EU pharmacy with your e-prescription.
- 4-week check-in
Ongoing support
Private chat, 4-week check-in, simple prescription renewal.
NOTIFY ME
We'll tell you when we add new treatments.
We only use your email for this notification. You can opt out at any time.
FREQUENTLY ASKED QUESTIONS